So, if a person had 100 different antibodies against chicken pox before contracting measles, they might emerge from a case of measles with only 50, cutting their chicken pox protection in half. That protection could dip even lower if some of the antibodies lost are potent defenses known as neutralizing antibodies.

“Imagine that your immunity against pathogens is like carrying around a book of photographs of criminals, and someone punched a bunch of holes in it,” said the study’s first author, Michael Mina, a postdoctoral researcher in the laboratory of Stephen Elledge at HMS and BWH at the time of the study, and now an assistant professor of epidemiology at the Harvard Chan School.

“It would then be much harder to recognize that criminal if you saw them, especially if the holes are punched over important features for recognition, like the eyes or mouth,” said Mina.

The study is the first to measure the immune damage caused by the virus and underscores the value of preventing measles infection through vaccination, the authors said.

“The threat measles poses to people is much greater than we previously imagined,” said senior author Elledge, the Gregor Mendel Professor of Genetics and of Medicine in the Blavatnik Institute at Harvard Medical School and Brigham and Women’s Hospital. “We now understand the mechanism is a prolonged danger due to erasure of the immune memory, demonstrating that the measles vaccine is of even greater benefit than we knew.”

The discovery that measles depletes people’s antibody repertoires, partially obliterating immune memory to most previously encountered pathogens, supports the immune amnesia hypothesis.

“This is the best evidence yet that immune amnesia exists and impacts our bona fide long-term immune memory,” added Mina, who first discovered the epidemiological effects of measles on long-term childhood mortality in a 2015 paper.

The team’s current work was published simultaneously with a paper by a separate team in Science Immunology that reached complementary conclusions by measuring changes in B cells caused by the measles virus. An accompanying editorial in Science Immunology, written by Duane Wesemann, HMS assistant professor of medicine at BWH, contextualizes that study.

One of the most contagious diseases known to humankind, measles killed an average of 2.6 million people each year before a vaccine was developed. — World Health Organization

Elledge, Mina, and colleagues found that those who survive measles gradually regain their previous immunity to other viruses and bacteria as they get re-exposed to them. But because this process may take months to years, people remain vulnerable in the meantime to serious complications of those infections.

In light of this finding, the researchers say clinicians may want to consider strengthening the immunity of patients recovering from measles infection with a round of booster shots of all previous routine vaccines, such as hepatitis and polio.

“Revaccination following measles could help to mitigate long-term suffering that might stem from immune amnesia and the increased susceptibility to other infections,” the authors said.

Two steps forward, one step back

One of the most contagious diseases known to humankind, measles killed an average of 2.6 million people each year before a vaccine was developed, according to the World Health Organization (WHO). Widespread vaccination has slashed the death toll.

However, lack of access to vaccination and refusal to get vaccinated means measles still infects more than 7 million people and kills more than 100,000 each year worldwide, reports the WHO — and cases are on the rise, tripling in early 2019. About 20 percent of people in the U.S. who get infected with measles require hospitalization, according to the Centers for Disease Control and Prevention, and some experience well-known long-term consequences, including brain damage and vision and hearing loss.

Previous epidemiological research into immune amnesia suggests that death rates attributed to measles could be even higher — accounting for as much as 50 percent of all childhood mortality — if researchers factored in deaths caused by infections resulting from measles’ ravaging effects on immunity.

Answers in the blood

This new discovery was made possible thanks to VirScan , a tool Elledge and Tomasz Kula, a Graduate School of Arts and Sciences Ph.D. student in the Elledge Lab, developed in 2015.

VirScan detects antiviral and antibacterial antibodies in the blood that result from current or past encounters with viruses and bacteria, giving an overall snapshot of the immune system.

Study co-author Rik de Swart had gathered blood samples from unvaccinated children during a 2013 measles outbreak in the Netherlands. For the new study, Elledge’s group used VirScan to measure antibodies before and two months after infection in 77 children from de Swart’s samples who’d contracted the disease. The researchers also compared the measurements to those of 115 uninfected children and adults.

When Kula examined an initial set of these samples, he found a striking drop in antibodies from other pathogens in the measles-infected children that “clearly suggested a direct effect on the immune system,” the authors said.

The effect resembled what Mina had hypothesized could drive measles-induced immune amnesia.

“This proved to be the first definitive evidence that measles affects the levels of protective antibodies themselves, providing a mechanism supporting immune amnesia,” said Elledge.

Then, in collaboration with Diane Griffin at Johns Hopkins Bloomberg School of Public Health, the team measured antibodies in four rhesus macaques — monkeys closely related to humans — before and five months after measles infection. This covered a much longer period postinfection than that available in the Netherlands samples.

Similar to the findings in people, the macaques lost an average of 40 to 60 percent of their pre-existing antibodies to the viruses and bacteria to which they had been previously exposed.

Further tests revealed that severe measles infection reduced people’s overall immunity more than mild infection. This could be particularly problematic for certain categories of children and adults, the researchers said.

The authors stress that the effects observed in the current study occurred in previously healthy children. Because measles is known to hit malnourished children much harder, the degree of immune amnesia and its effects could be even more severe in less-healthy populations.

“The average kid might emerge from measles with a dent in their immune system and their body will be able to handle that,” said Elledge. “But kids on the edge — such as those with severe measles infection or immune deficiencies or those who are malnourished — will be in serious trouble.”

Vital vaccination

Inoculation with the MMR (measles, mumps, rubella) vaccine did not impair children’s overall immunity, the researchers found. The results align with decades of research.

Ensuring widespread vaccination against measles would not only help prevent the 120,000 deaths that will be directly attributed to measles this year alone, but could also avert potentially hundreds of thousands of additional deaths attributable to the lasting damage to the immune system, the authors said.

“This drives home the importance of understanding and preventing the long-term effects of measles, including stealth effects that have flown under the radar of doctors and parents,” said Mina. “If your child gets the measles and then gets pneumonia two years later, you wouldn’t necessarily tie the two together. The symptoms of measles itself may be only the tip of the iceberg.”

Yumei Leng and Mamie Li of the Elledge Lab are co-authors of the study. Additional authors are affiliated with the University Medical Centre Rotterdam, University of Helsinki, Helsinki University Hospital, University of Colorado School of Medicine, Genentech, Johns Hopkins University School of Medicine, and Duke University Medical Center.

This study was supported by the Value of Vaccination Research Network, Gates Foundation, National Institutes of Health (grants U24AI118633, R01DK032493, R21AI095981, and R01AI131228), European Union Seventh Framework Programme (grant 202063), Academy of Finland (grant 250114), and PREPARE Europe (EU FP7 grant 602525). Elledge is an investigator of the Howard Hughes Medical Institute.